The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.